1.66 USD
▲+0.06+3.75%
盘后 2.02 0.00%
2026-09-16
市值
$28.44M
市盈率
—
EPS
-51.08
股息率
—
52 周区间
1.58 – 20.99
成交量
16.58K
Beta
1.17
目标价
—
52W 低 1.5852W 高 20.99
价格走势
公司简介
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company’s therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical...